2658-6533Research Results in Biomedicine2658-653310.18413/2658-6533-2021-7-4-0-22555Genetics<strong>Ovarian cancer as part of hereditary cancer syndromes (review)</strong><strong>Ovarian cancer as part of hereditary cancer syndromes (review)</strong>ValovaYana V.ValovaYana V.Q.juk@yandex.ruMingazhevaElvira T.MingazhevaElvira T.elvira.f91@mail.ruProkofievaDarya S.ProkofievaDarya S.dager-glaid@yandex.ruValievRuslan R.ValievRuslan R.ruslan_valiev@mail.ruNurgalievaAlfiya Kh.NurgalievaAlfiya Kh.alfiyakh83@gmail.comKhusnutdinovaElza K.KhusnutdinovaElza K.elzakh@mail.ru20217400

Background:&nbsp;Hereditary forms of ovarian cancer (OC) account for more than one fifth of cases of malignant neoplasms of this localization. The discovery of new molecular genetic predictors of OC development led to the improvement of the early diagnosis system and therapeutic approaches to treatment, which significantly reduced mortality from this oncopathology. However, existing screening systems cover only a small range of pathogenic variants, which is why their predictive value is greatly reduced. The aim of the study:&nbsp;Based on the study of modern literature data, to consider the representation of ovarian cancer in the composition of hereditary sidromes and to assess the contribution of genetic factors to the development of hereditary forms of ovarian cancer. Materials and methods:&nbsp;Analysis of the literature data was carried out using the keywords: hereditary ovarian cancer, breast and ovarian cancer syndrome, Cowden&#39;s syndrome, Lynch&#39;s syndrome, Nijmegen&#39;s syndrome, ataxia-telangiectasia, Fanconi anemia, Peitz-Jegers syndrome for the period 1981-2021 in databases: PubMed, PMC, eLibrary. Results:&nbsp;The syndrome of breast and ovarian cancer is the most common form of familial ovarian cancer, which in 65-85% of cases is caused by germline mutations in the BRCA1 / BRCA2 genes. However, to date, at least six more tumor syndromes are known associated with hereditary OC and caused by mutations in other suppressor genes and oncogenes, including genes MSH6, MLH1, MSH2 (Lynch syndrome), NBN (Nijmegen syndrome), ATM (ataxia telangiectasia), STK11 (Peitz-Jegers syndrome), RAD51C, RAD51D, BRIP1, PALB (Fanconi&#39;s anemia), PTEN (Cowden&#39;s syndrome). Germline mutations in these genes are responsible for about 15-20% of cases of hereditary forms of OC. Nevertheless, the spectrum of pathogenic variants in these genes and their contribution to the development of OC has been insufficiently studied, which complicates the development of molecular diagnostic strategies. Conclusion:&nbsp;The development and implementation of the latest sequencing technologies have made it possible to expand knowledge of the molecular mechanisms of ovarian tumor formation and to identify many new molecular markers of this process. However, the contribution of the identified variants to the formation of predisposition to OC has been insufficiently studied and requires further research.

Background:&nbsp;Hereditary forms of ovarian cancer (OC) account for more than one fifth of cases of malignant neoplasms of this localization. The discovery of new molecular genetic predictors of OC development led to the improvement of the early diagnosis system and therapeutic approaches to treatment, which significantly reduced mortality from this oncopathology. However, existing screening systems cover only a small range of pathogenic variants, which is why their predictive value is greatly reduced. The aim of the study:&nbsp;Based on the study of modern literature data, to consider the representation of ovarian cancer in the composition of hereditary sidromes and to assess the contribution of genetic factors to the development of hereditary forms of ovarian cancer. Materials and methods:&nbsp;Analysis of the literature data was carried out using the keywords: hereditary ovarian cancer, breast and ovarian cancer syndrome, Cowden&#39;s syndrome, Lynch&#39;s syndrome, Nijmegen&#39;s syndrome, ataxia-telangiectasia, Fanconi anemia, Peitz-Jegers syndrome for the period 1981-2021 in databases: PubMed, PMC, eLibrary. Results:&nbsp;The syndrome of breast and ovarian cancer is the most common form of familial ovarian cancer, which in 65-85% of cases is caused by germline mutations in the BRCA1 / BRCA2 genes. However, to date, at least six more tumor syndromes are known associated with hereditary OC and caused by mutations in other suppressor genes and oncogenes, including genes MSH6, MLH1, MSH2 (Lynch syndrome), NBN (Nijmegen syndrome), ATM (ataxia telangiectasia), STK11 (Peitz-Jegers syndrome), RAD51C, RAD51D, BRIP1, PALB (Fanconi&#39;s anemia), PTEN (Cowden&#39;s syndrome). Germline mutations in these genes are responsible for about 15-20% of cases of hereditary forms of OC. Nevertheless, the spectrum of pathogenic variants in these genes and their contribution to the development of OC has been insufficiently studied, which complicates the development of molecular diagnostic strategies. Conclusion:&nbsp;The development and implementation of the latest sequencing technologies have made it possible to expand knowledge of the molecular mechanisms of ovarian tumor formation and to identify many new molecular markers of this process. However, the contribution of the identified variants to the formation of predisposition to OC has been insufficiently studied and requires further research.

hereditary ovarian cancerbreast and ovarian cancer syndromeCowden's syndromeLynch's syndromeNijmegen's syndromeataxia-telangiectasiaFanconi anemiaPeitz-Jegers syndromehereditary ovarian cancerbreast and ovarian cancer syndromeCowden's syndromeLynch's syndromeNijmegen's syndromeataxia-telangiectasiaFanconi anemiaPeitz-Jegers syndrome

Yana V. Valova thanks the Russian Foundation for Basic Research (Project No. 20-34-90003) for financial support of this work. Prokofieva D.S. thanks the Ministry of Science and Higher Education of the Russian Federation (State Assignment No. 075-03-2021-193/5) for financial support of this work. Mingazheva E.T. thanks the Russian Foundation for Basic Research (Project No. 18-29-09129) for financial support of this work

Список литературыAllemani C, Weir HK, Carreira H, et al. Global surveillance of cancer survival 1995&ndash;2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2). The Lancet. 2015;385(9972):977-1010. DOI: https://doi.org/10.1016/S0140-6736(14)62038-9Kaprin АD, Starinskogo VV, Shahzadov АО. The state of cancer care for the population of Russia in 2019. М.: МNIOI P.А. Gerzena; 2020.Zhordania KI, Kalinicheva EV, Moiseev AA Ovarian cancer: epidemiology, morphology and histogenesis. Oncogynecology. 2017;3:26-32. Russian.Hanson KP, Imyanitov EN. Molecular genetics of ovarian cancer. Practical oncology. 2000;4:3-6. Russian.Liu L, Hao X, Song Z, et al. Correlation between family history and characteristics of breast cancer.&nbsp;Scientific Reports.&nbsp;2021;11(1):1-12. https://doi.org/10.1038/s41598-021-85899-8Toss A, Tomasello C, Razzaboni E, et al. Hereditary ovarian cancer: not only BRCA 1 and 2 genes. BioMed Research International. 2015;2015:341723. DOI: https://doi.org/10.1155/2015/341723Angeli D, Salvi S, Tedaldi G. Genetic Predisposition to Breast and Ovarian Cancers: How Many and Which Genes to Test? International Journal of Molecular Sciences. 2020;21(3):1128. DOI: https://doi.org/10.3390/ijms21031128Laptiev SA, Korzhenevskaia MA, Sokolenko AP, et al. Medical and genetic counseling of hereditary breast and ovarian cancer. The Scientific Notes of the Pavlov University. 2018;25(2):7-18. Russian. DOI: https://doi.org/10.24884/1607-4181-2018-25-2-7-18Nikitin AG, Brovkina OI, Khodyrev DS, et al. Experience in creating a public database of oncoBRCA mutations: bioinformation problems and solutions. Clinical practice. 2020;11(1):21-29. Russan. DOI: https://doi.org/10.17816/clinpract25860Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA - Journal of the American Medical Association. 2017;317(23):2402-2416. DOI: 10.1001/jama.2017.7112Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266(5182):66-71. DOI: https://doi.org/10.1126/science.7545954Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995;378(6559):789-792. DOI: https://doi.org/10.1038/378789a0Gudmundsdottir K, Ashworth A. The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene. 2006;25(43):5864-5874. DOI: https://doi.org/10.1038/sj.onc.1209874Golmard L, Delnatte C, Laug&eacute; A, et al. Breast and ovarian cancer predisposition due to de novo BRCA1 and BRCA2 mutations. Oncogene. 2016;35(10):1324-1327. DOI: https://doi.org/10.1038/onc.2015.181Paluch-Shimon S, Cardoso F, Sessa C, et al. Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening. Annals of Oncology. 2016;27:v103-v110. DOI: https://doi.org/10.1093/annonc/mdw327Rebbeck TR, Friebel TM, Friedman E, et al. Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations.&nbsp;Human Mutation.&nbsp;2018;39(5):593-620. DOI: https://doi.org/10.1002/humu.23406Heramb C, Wangensteen T, Grindedal EM, et al. BRCA1 and BRCA2 mutation spectrum&ndash;an update on mutation distribution in a large cancer genetics clinic in Norway. Hereditary Cancer in Clinical Practice. 2018;16(1):1-15. DOI: https://doi.org/10.1186/s13053-017-0085-6Ferla R, Calo V, Cascio S, et al. Founder mutations in BRCA1 and BRCA2 genes. Annals of Oncology. 2007;18:93-98. DOI: https://doi.org/10.1093/annonc/mdm234Thorlacius S, Olafsdottir G, Tryggvadottir L, et al. A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nature Genetics. 1996;13(1):117-119. DOI: https://doi.org/10.1038/ng0596-117Oros KK, Ghadirian P, Maugard CM, et al. Application of BRCA1 and BRCA2 mutation carrier prediction models in breast and/or ovarian cancer families of French Canadian descent. Clinical Genetics. 2006;70(4):320-329. DOI: https://doi.org/10.1111/j.1399-0004.2006.00673.xTonin PN, Mes‐Masson AM, Narod SA, et al. Founder BRCA1 and BRCA2 mutations in French Canadian ovarian cancer cases unselected for family history. Clinical Genetics. 1999;55(5):318-324. DOI: https://doi.org/10.1034/j.1399-0004.1999.550504.xGorski B, Byrski T, Huzarski T, et al. Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. American Journal of Human Genetics. 2000;66(6):1963-1968. DOI: https://doi.org/10.1086/302922Hamel N, Feng BJ, Foretova L, et al. On the origin and diffusion of BRCA1 c.5266dupC (5382insC) in European populations. European Journal of Human Genetics. 2011;19(3):300-6. DOI: https://doi.org/10.1038/ejhg.2010.203Villarreal‐Garza C, Alvarez‐G&oacute;mez RM, P&eacute;rez‐Plasencia C, et al. Significant clinical impact of recurrent BRCA1 and BRCA2 mutations in Mexico. Cancer. 2015;121(3):372-378. DOI: &nbsp;https://doi.org/10.1002/cncr.29058Ramus SJ, Kote-Jarai Z, Friedman LS, et al. Analysis of BRCA1 and BRCA2 mutations in Hungarian families with breast or breast-ovarian cancer. American Journal of Human Genetics. 1997;60(5):1242.Van der Looij M, Szabo C, Besznyak I, et al. Prevalence of founder BRCA1 and BRCA2 mutations among breast and ovarian cancer patients in Hungary. International Journal of Cancer. 2000;86(5):737-740. DOI: https://doi.org/10.1002/(SICI)1097-0215(20000601)86:5&lt;737::AID-IJC21&gt;3.0.CO;2-1Bermisheva MA, Bogdanova NV, Gilyazova IR, et al. Ethnic features of the formation of genetic predisposition to the development of breast cancer. Genetics. 2018;54(2):233-242. Russian. DOI: https://doi.org/10.7868/S0016675818020042Faiskhanova RR. Features of the clinical course and molecular genetic characteristics of hereditary ovarian cancer [dissertation]. Moscow; 2021. Russian.Sokolenko AP, Sokolova TN, Ni VI, et al. Frequency and spectrum of founder and non-founder BRCA1 and BRCA2 mutations in a large series of Russian breast cancer and ovarian cancer patients. Breast Cancer Research and Treatment. 2020;184(1):229-235. DOI: https://doi.org/10.1007/s10549-020-05827-8Bogomolova OA, Shatova YUS, Vereskunova MI, et al. Germinal mutations in the BRCA1 and BRCA2 genes in patients in the South of Russia with clinical signs of hereditary breast cancer. Modern problems of science and education. 2017;5:114-114. Russian.Przhedetsky YV, Vodolazhsky DI, Shatova YUS, et al. BRCA mutations in patients with clinical signs of hereditary breast cancer in the southern federal district. Malignant tumors. 2015;4-2(16):121-122. Russian.Brovkina OI, Gordiev MG, Enikeev RF, et al. Reparation system genes: population differences in hereditary ovarian and breast cancer determined by next-generation sequencing. Tumors of female reproductive system. 2017;13(2):61-67. Russian. DOI: https://doi.org/10.17650/1994-4098-2017-13-2-61-67Lyubchenko LN. Hereditary breast and / or ovarian cancer: DNA diagnostics, individual prognosis, treatment and prevention [dissertation]. Moscow; 2009.Goode ELA genome-wide association study identies susceptibility loci for ovar-ian cancer at 2q31 and 8q24. Nature Genetics. 2010;42(10):874-879. DOI: https://doi.org/10.1038/ng.668Ramus SJ, Antoniou AC, Kuchenbaecker KB, et al. Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Human Mutation. 2012;33(4):690-702. DOI: https://doi.org/10.1002/humu.22025Kuchenbaecker KB, Ramus SJ, Tyrer J, et al. Identification of six new susceptibility loci for invasive epithe-lial ovarian cancer. Nature Genetics. 2015;47(2):164-171. DOI: https://doi.org/10.1038/ng.3185Lynch HT, Krush AJ. Heredity and adenocarcinoma of the colon. Gastroenterology. 1967;53(4):517-527. DOI: https://doi.org/10.1016/S0016-5085(19)34179-4Lynch HT, Lynch JF, Lynch PM, et al. Hereditary colorectal cancer syndromes: molecular genetics, genetic counseling, diagnosis and management. Familial Cancer. 2008;7(1):27-39. DOI: https://doi.org/10.1007/s10689-007-9165-5Lynch HT, Casey MJ, Snyder CL, et al. Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management. Molecular Oncology. 2009;3(2):97-137. DOI: https://doi.org/10.1016/j.molonc.2009.02.004.Guillotin D, Martin SA. Exploiting DNA mismatch repair deficiency as a therapeutic strategy. Experimental Cell Research. 2014;329(1):110-115. DOI: https://doi.org/10.1016/j.yexcr.2014.07.004Ferreira AM, Westers H, Sousa S, et al. Mononucleotide precedes dinucleotide repeat instability during colorectal tumour development in Lynch syndrome patients. The Journal of Pathology: A Journal of the Pathological Society of Great Britain and Ireland. 2009;219(1):96-102. DOI:https://doi.org/10.1002/path.2573Toss A, Molinaro E, Sammarini M, et al. Hereditary ovarian cancers: state of the art. Minerva Medica. 2019;110:301-319. DOI: https://doi.org/10.23736/s0026-4806.19.06091-9Amin N, Chaabouni N, George A. Genetic testing for epithelial ovarian cancer. Best Practice and Research in Clinical Obstetrics and Gynaecology. 2020;65:125-38 DOI: https://doi.org/10.1016/j.bpobgyn.2020.01.005Pal T, Permuth‐Wey J, Sellers TA. A review of the clinical relevance of mismatch‐repair deficiency in ovarian cancer. Cancer. 2008;113(4):733‐742. DOI: https://doi.org/10.1002/cncr.23601Xiao X, Melton DW, Gourley C. Mismatch repair deficiency in ovarian cancer &ndash; molecular characteristics and clinical implications. Gynecologic Oncology. 2014;132(2):506‐512. DOI: https://doi.org/10.1016/j.ygyno.2013.12.003Crosbie EJ, Ryan NA, McVey, et al. Assessment of mismatch repair deficiency in ovarian cancer. Journal of Medical Genetics. 2021;58(10):687-691. DOI http://dx.doi.org/10.1136/jmedgenet-2020-107270Burgess BT, Kolesar JM. Defective DNA repair in hereditary ovarian cancers: Implications for therapy. American Journal of Health-System Pharmacy. 2018;75(21):1697-1707. DOI: https://doi.org/10.2146/ajhp180124Blanco I, Sijmons RH, et al. Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: A report from the Prospective Lynch Syndrome Database. Gut 2018;67(7):1306-1316.Kurian AW, Hughes E, Handorf EA, et al. Breast and ovarian cancer penetrance estimates derived from germline multiple-gene sequencing results in women. JCO Precision Oncology. 2017;1:1-12. DOI: 10.1200/PO.16.00066Sanne W, van der Klift HM, Tops CM, et al. Cancer risks for PMS2-associated Lynch syndrome. Journal of Clinical Oncology. 2018;36(29):2961-2968. DOI:&nbsp;https://doi.org/10.1200/JCO.2018.78.4777Lilyquist J, LaDuca H, Polley E, et al. Frequency of mutations in a large series of clinically ascertained ovarian cancer cases tested on multi-gene panels compared to reference controls. Gynecologic Oncology. 2017;147(2):375-380. DOI: https://doi.org/10.1016/j.ygyno.2017.08.030Cast&eacute;ra L, Harter V, Muller E, et al Landscape of pathogenic variations in a panel of 34 genes and cancer risk estimation from 5131 HBOC families. Genetics in Medicine. 2018;20(12):1677-1686. DOI: https://doi.org/10.1038/s41436-018-0005-9Suszynska M, Klonowska K, Jasinska AJ, et al. Large-scale meta-analysis of mutations identified in panels of breast/ovarian cancer-related genes &ndash; Providing evidence of cancer predisposition genes. Gynecologic Oncology. 2019;153(2):452-462. DOI: https://doi.org/10.1016/j.ygyno.2019.01.027Lu HM, Li S, Black MH, et al. Association of breast and ovarian cancers with predisposition genes identified by large-scale sequencing. JAMA Oncology.&nbsp;2019;5(1):51-57. DOI: https://doi.org/10.1001/jamaoncol.2018.2956Song H, Cicek MS, Dicks E, et al. The contribution of deleterious germline mutations in BRCA1, BRCA2 and the mismatch repair genes to ovarian cancer in the population.&nbsp;Human Molecular Genetics.&nbsp;2014;23(17):4703-4709. DOI: https://doi.org/10.1093/hmg/ddu172Akbari MR, Zhang S, Cragun D, et al. Correlation between germline mutations in MMR genes and microsatellite instability in ovarian cancer specimens.&nbsp;Familial Cancer. 2017:16(3):351-355. DOI: https://doi.org/10.1007/s10689-017-9973-1Walsh T, Casadei S, Lee MK, et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing.&nbsp;Proceedings of the National Academy of Sciences. 2011;108(44):18032-18037. DOI: https://doi.org/10.1073/pnas.1115052108Pal T, Akbari MR, Sun P, et al. Frequency of mutations in mismatch repair genes in a population-based study of women with ovarian cancer. British Journal of Cancer. 2012;107(10):1783-1790. DOI: https://doi.org/10.1038/bjc.2012.452Ambrose M, Gatti RA. Pathogenesis of ataxia-telangiectasia: the next generation of ATM functions. Blood, The Journal of the American Society of Hematology. 2013;121(20):4036-4045. DOI: https://doi.org/10.1182/blood-2012-09-456897Amirifar P, Ranjouri MR, Yazdani R, et al. Ataxia‐telangiectasia: A review of clinical features and molecular pathology. Pediatric Allergy and Immunology. 2019;30(3):277-288. DOI: https://doi.org/10.1111/pai.13020Swift M, Reitnauer PJ, Morrell D, et al. Breast and other cancers in families with ataxia-telangiectasia. New England Journal of Medicine. 1987;316(21):1289-1294. DOI: https://doi.org/10.1056/NEJM198705213162101Kurian AW, Ward KC, Howlader N, et al. Genetic testing and results in a population-based cohort of breast cancer patients and ovarian cancer patients. Journal of Clinical Oncology. 2019;37(15):1305. DOI: https://doi.org/10.1200/JCO.18.01854Norquist BM, Harrell MI, Brady MF, et al. Inherited Mutations in Women with Ovarian Carcinoma. JAMA Oncology. 2016;2:482-490. DOI: 10.1001/jamaoncol.2015.5495Jerzak KJ, Mancuso T, Eisen A. Ataxia&ndash;telangiectasia gene (ATM) mutation heterozygosity in breast cancer: a narrative review. Current Oncology. 2018;25(2):176-180. DOI: https://doi.org/10.3747/co.25.3707Koczkowska M, Krawczynska N, Stukan M, et al. Spectrum and prevalence of pathogenic variants in ovarian cancer susceptibility genes in a group of 333 patients. Cancers. 2018;10(11):442. DOI: https://doi.org/10.3390/cancers10110442Thorstenson YR, Roxas A, Kroiss R, et al. Contributions of ATM mutations to familial breast and ovarian cancer. Cancer research. 2003;63(12):3325-3333.Podralska MJ, Stembalska A, Ślęzak R, et al. Ten new ATM alterations in Polish patients with ataxia‐telangiectasia. Molecular genetics &amp; genomic medicine. 2014;2(6):504-511. DOI: https://doi.org/10.1002/mgg3.98Southey MC, Goldgar DE, Winqvist R, et al. PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. Journal of Medical Genetics. 2016;53(12):800-811. DOI: http://dx.doi.org/10.1136/jmedgenet-2016-103839Waddell N, Jonnalagadda J, Marsh A, et al. Characterization of the breast cancer associated ATM 7271T&gt;G (V2424G) mutation by gene expression profiling. Genes Chromosomes and Cancer. 2006;45:1169-81. DOI: https://doi.org/10.1002/gcc.20381Hall MJ, Bernhisel R, Hughes E, et al. Germline pathogenic variants in the Ataxia Telangiectasia Mutated (ATM) gene are associated with high and moderate risks for multiple cancers. Cancer Prevention Research. 2021;14(4):433-440. &nbsp;https://doi.org/10.1158/1940-6207.CAPR-20-0448Weemaes CMR, Hustinx TWJ, Scheres JMJ, et al A new chromosomal instability disorder: the Nijmegen breakage syndrome. Acta Paediatrica. 1981;70(4):557-564. DOI: https://doi.org/10.1111/j.1651-2227.1981.tb05740.xVan Der Burgt I, Chrzanowska KH, Smeets DFCM, et al. Nijmegen breakage syndrome. Journal of Medical Genetics. 1996;33(2):153-156. DOI: http://dx.doi.org/10.1136/jmg.33.2.153Wen J, Cerosaletti K, Schultz KJ, et al. NBN phosphorylation regulates the accumulation of MRN and ATM at sites of DNA double-strand breaks. Oncogene. 2013;32(37):4448-4456. DOI: https://doi.org/10.1038/onc.2012.443Rupnik A, Lowndes NF, Grenon M. MRN and the race to the break. Chromosoma. 2010;119:115-135. DOI: https://doi.org/10.1007/s00412-009-0242-4Ramus SJ, Song H, Dicks E. Germline mutations in the BRIP1, BARD1, PALB2, and NBN genes in women with ovarian cancer. Journal of the National Cancer Institute. 2015;107(11):djv214. DOI: https://doi.org/10.1093/jnci/djv214Lhotova K, Stolarova L, Zemankova P, et al. Multigene panel germline testing of 1333 Czech patients with ovarian cancer. Cancers. 2020;12(4):956. DOI: https://doi.org/10.3390/cancers12040956Seemanova E, Varon R, Vejvalka J, et al. The Slavic NBN founder mutation: a role for reproductive fitness? PLoS ONE. 2016;11(12):e0167984. DOI: https://doi.org/10.1371/journal.pone.0167984Cybulski C, Kluźniak W, Huzarski T, et al. The spectrum of mutations predisposing to familial breast cancer in Poland. International Journal of Cancer. 2019;145(12):3311-3320. DOI: https://doi.org/10.1002/ijc.32492Lins S, Kim R, Kr&uuml;ger L, et al. Clinical variability and expression of the NBN c. 657del5 allele in Nijmegen Breakage Syndrome. Gene. 2009;447(1):12-17. DOI: https://doi.org/10.1016/j.gene.2009.07.013Suspitsin EN, Sherina NY, Ponomariova DN, et al. High frequency of BRCA1, but not CHEK2 or NBS1 (NBN), founder mutations in Russian ovarian cancer patients. Hereditary Cancer in Clinical Practice. 2009;7(1):1-7. DOI: https://doi.org/10.1186/1897-4287-7-5Bateneva YI, Filippova MG, Tyulyandina AS, et al. High rate of mutations in the BRCA1, BRCA2, CHEK2, NBN, and BLM genes in Russian ovarian cancer patients. Tumors of female reproductive system. 2014;(4):51-56. Russian. DOI: https://doi.org/10.17650/1994-4098-2014-0-4-51-56Krivokuca A, Boljevic I, Jovandic S, et al. Germline mutations in cancer susceptibility genes in high grade serous ovarian cancer in Serbia. Journal of Human Genetics. 2019;64(4):281-290. DOI: https://doi.org/10.1038/s10038-019-0562-zBogdanova N, Sch&uuml;rmann P, Waltes R, et al. NBS1 variant I171V and breast cancer risk. . 2008;(1):75-79. DOI: https://doi.org/10.1007/s10549-007-9820-4Nowak J, Mosor M, Zi&oacute;łkowska I, et al. Heterozygous carriers of the I171V mutation of the NBS1 gene have a significantly increased risk of solid malignant tumours. . 2008;(4):627-630. DOI: https://doi.org/10.1016/j.ejca.2008.01.006Rożnowski K, Januszkiewicz-Lewandowska D, Mosor M, et al. I171V germline mutation in the NBS1 gene significantly increases risk of breast cancer. . 2008;(2):343-348. DOI: https://doi.org/10.1007/s10549-007-9734-1Bermisheva MA, Bogdanova NV, Zinnatullina GF et al. Analysis of mutations a657del5 and p. R215W in the NBN gene in breast cancer patients in the Republic of Bashkortostan and Khanty-Mansi Autonomous Okrug. Medical genetics.&nbsp;2009;8(8):36-40.Stafford JL, Dyson G, Levin NK, et al. Reanalysis of BRCA1/2 negative high risk ovarian cancer patients reveals novel germline risk loci and insights into missing heritability.&nbsp;. 2017;(6):e0178450. DOI: https://doi.org/10.1371/journal.pone.0178450Elkholi IE, Di Iorio M, Fahiminiya S, et al. Investigating the causal role of MRE11A p. E506* in breast and ovarian cancer. . 2021;(1):1-9. DOI: https://doi.org/10.1038/s41598-021-81106-wHeikkinen K, Karppinen SM, Soini Y, et al. Mutation screening of Mre11 complex genes: indication of RAD50 involvement in breast and ovarian cancer susceptibility. . 2003;(12):e131-e131. DOI: http://dx.doi.org/10.1136/jmg.40.12.e131Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. . 1997;(5308):1943-1947. DOI: 10.1126/science.275.5308.1943Pezzolesi MG, Zbuk KM, Waite K, et al. Comparative genomic and functional analyses reveal a novel cis-acting PTEN regulatory element as a highly conserved functional E-box motif deleted in Cowden syndrome. Human Molecular Genetics.2007;16:1058-1071. DOI: https://doi.org/10.1093/hmg/ddm053Mester J, Eng C. Cowden syndrome: Recognizing and managing a not-so-rare hereditary cancer syndrome. Journal of Surgical Oncology.2015;111:125-130. DOI: https://doi.org/10.1002/jso.23735Tan MH, Mester JL, NgeowJ, et al. Lifetime cancer risks in individuals with germline PTEN mutations. . 2012;(2):400-407. &nbsp;https://doi.org/10.1158/1078-0432.CCR-11-2283Angeli D, Salvi S, Tedaldi G. Genetic Predisposition to Breast and Ovarian Cancers: How Many and Which Genes to Test? . 2020;(3):1128. DOI: https://doi.org/10.3390/ijms21031128Kurman RJ, Shih IM. The Origin and pathogenesis of epithelial ovarian cancer-a proposed unifying theory. . 2010;(3):433. DOI:&nbsp;https://doi.org/10.1097/PAS.0b013e3181cf3d79Sato N, Tsunoda H, Nishida M, et al. Loss of heterozygosity on 10q23. 3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. . 2000;(24):7052-7056.Kolasa IK, Rembiszewska A, Janiec-Jankowska A, et al. PTEN mutation, expression and LOH at its locus in ovarian carcinomas. Relation to TP53, K-RAS and BRCA1 mutations. Gynecologic Oncology. 2006;103(2):692-697. DOI: https://doi.org/10.1016/j.ygyno.2006.05.007Xu B, Hamada S, Kusuki I, et al. Possible involvement of loss of heterozygosity in malignant transformation of ovarian endometriosis. 2011;(2):239-246. DOI: https://doi.org/10.1016/j.ygyno.2010.10.036Cho MY, Kim HS, Eng C, et al. First report of ovarian dysgerminoma in Cowden syndrome with germline PTEN mutation and PTEN-related 10q loss of tumor heterozygosity. . 2008;(8):1258-1264. DOI: https://doi.org/10.1097/PAS.0b013e31816be8b7Matsubayashi H, Higashigawa S, Kiyozumi Y, et al. Metachronous ovarian endometrioid carcinomas in a patient with a PTEN variant: case report of incidentally detected Cowden syndrome. . 2019;(1):1-5. DOI: https://doi.org/10.1186/s12885-019-6272-2Yauy K, Imbert-Bouteille M, Bubien V, et al. Ovarian clear cell carcinoma in Cowden syndrome. . 2019;(1):7-11. DOI: https://doi.org/10.6004/jnccn.2018.7065Xu X, Jin D, Durgan J, et al. LKB1 controls human bronchial epithelial morphogenesis through p114RhoGEF-dependent RhoA activation. . 2013;(14):2671-2682.https://doi.org/10.1128/MCB.00154-13Resta N, Pierannunzio D, Lenato GM, et al. Cancer risk associated with STK11/LKB1 germline mutations in Peutz&ndash;Jeghers syndrome patients: Results of an Italian multicenter study. . 2013;(7):606-611. DOI: https://doi.org/10.1016/j.dld.2012.12.018Van Lier MGF, Wagner A, Mathus-Vliegen EMH, et al. High cancer risk in Peutz&ndash;Jeghers syndrome: a systematic review and surveillance recommendations. . 2010;(6):1258-1264. DOI: https://doi.org/10.1038/ajg.2009.725Neto N, Cunha TM. Do hereditary syndrome-related gynecologic cancers have any specific features? . 2015;(5):545-552. DOI: https://doi.org/10.1007/s13244-015-0425-xLi W, Shao D, Li L, et al. Germline and somatic mutations of multi-gene panel in Chinese patients with epithelial ovarian cancer: a prospective cohort study. . 2019;(1):1-9. DOI: https://doi.org/10.1186/s13048-019-0560-yShao D, Cheng S, Guo F, et al. Prevalence of hereditary breast and ovarian cancer (HBOC) predisposition gene mutations among 882 HBOC high‐risk Chinese individuals. . 2020;(2):647-657. DOI: https://doi.org/10.1111/cas.14242Human Gene Mutation Database [HGMD] [Internet] [cited 2021 Oct 22]. Russian. Available from: http://www.hgmd.cf.ac.ukChakravarty D, Gao J, Phillips S, et al. OncoKB: a precision oncology knowledge base. . 2017;:1-16. DOI: https://doi.org/10.1200/PO.17.00011Lee G, Kim JH, Lee SN, et al. Prevalence of pathogenic mutations in Korean hereditary breast-ovarian cancer. . 2018;:ix116. DOI: https://doi.org/10.1093/annonc/mdy441.012Jiang YL, Zhao ZY, Li BR, et al. STK11 gene analysis reveals a significant number of splice mutations in Chinese PJS patients. . 2019;:47-57. DOI: https://doi.org/10.1016/j.cancergen.2018.11.008Mamrak NE, Shimamura A, Howlett NG. Recent discoveries in the molecular pathogenesis of the inherited bone marrow failure syndrome Fanconi anemia. . 2017;(3):93-99. DOI: https://doi.org/10.1016/j.blre.2016.10.002Rosenberg PS, Tamary H, Alter BP. How high are carrier frequencies of rare recessive syndromes? Contemporary estimates for Fanconi Anemia in the United States and Israel. . 2011;(8):1877-1883. DOI: https://doi.org/10.1002/ajmg.a.34087Alter BP. Fanconi anemia and the development of leukemia. . 2014;(3-4):214-221. DOI: https://doi.org/10.1016/j.beha.2014.10.002Asur RS, Kimble DC, Lach FP, et al. Somatic mosaicism of an intragenic FANCB duplication in both fibroblast and peripheral blood cells observed in a Fanconi anemia patient leads to milder phenotype. . 2018;(1):77-91. DOI: https://doi.org/10.1002/mgg3.350Kottemann MC, Smogorzewska A. Fanconi anaemia and the repair of Watson and Crick DNA crosslinks. . 2013;(7432):356-363. DOI: https://doi.org/10.1038/nature11863Yang X, Leslie G, Doroszuk A, et al. Cancer risks associated with germline PALB2 pathogenic variants: an international study of 524 families. . 2020;(7):674. DOI:&nbsp;https://doi.org/10.1200/JCO.19.01907Xia B, Sheng Q, Nakanishi K, et al. Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. . 2006;(6):719-729. DOI: https://doi.org/10.1016/j.molcel.2006.05.022Zhang F, Fan Q, Ren K, et al. PALB2 functionally connects the breast cancer susceptibility proteins BRCA1 and BRCA2. . 2009;(7):1110-1118. &nbsp;https://doi.org/10.1158/1541-7786.MCR-09-0123Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clinical Cancer Research. 2014;20:764-775. DOI:Tung N, Lin NU, Kidd J, et al. Frequency of germline mutations in 25 cancer susceptibility genes in a sequential series of patients with breast cancer. Journal of Clinical Oncology. 2016;34:1460-1468. DOI: 10.1200/JCO.2015.65.0747Tischkowitz M, Sabbaghian N, Hamel N, et al. Contribution of the PALB2 c. 2323C&gt; T [p. Q775X] founder mutation in well-defined breast and/or ovarian cancer families and unselected ovarian cancer cases of French Canadian descent. . 2013;(1):1-7. DOI: https://doi.org/10.1186/1471-2350-14-5Ghadirian P, Robidoux A, Zhang P, et al. The contribution of founder mutations to early‐onset breast cancer in French‐Canadian women. Clinical Genetics. 2009;76(5):421-426.DOI: https://doi.org/10.1111/j.1399-0004.2009.01277.xDansonka-Mieszkowska A, Kluska A, Moes J, et al. A novel germline PALB2 deletion in Polish breast and ovarian cancer patients. . 2010;11(1):1-9. DOI: https://doi.org/10.1186/1471-2350-11-20Wojcik P, Jasi&oacute;wka M, Strycharz E, et al. Recurrent mutations of BRCA1, BRCA2 and PALB2 in the population of breast and ovarian cancer patients in Southern Poland. . 2016;(1):1-10. DOI: https://doi.org/10.1186/s13053-016-0046-5Noskowicz M, Bogdanova N, Bermisheva M, et al. Prevalence of PALB2 mutation c. 509_510delGA in unselected breast cancer patients from Central and Eastern Europe. . 2014;(2):137-142. DOI: https://doi.org/10.1007/s10689-013-9684-1Cybulski C, Kluźniak W, Huzarski T, et al. Clinical outcomes in women with breast cancer and a PALB2 mutation: a prospective cohort analysis. . 2015;(6):638-644. DOI: https://doi.org/10.1016/S1470-2045(15)70142-7Janatova M, Kleibl Z, Stribrna J, et al. The PALB2 gene is a strong candidate for clinical testing in BRCA1-and BRCA2-negative hereditary breast cancer. . 2013;(12):2323-2332. &nbsp;https://doi.org/10.1158/1055-9965.EPI-13-0745-THellebrand H, Sutter C, Honisch E, et al. Germline mutations in the PALB2 gene are population specific and occur with low frequencies in familial breast cancer. . 2011;(6):E2176-E2188. DOI: &nbsp;https://doi.org/10.1002/humu.21478Prokofyev D, Bogdanova N, Bermisheva M, et al. Rare occurrence of PALB2 mutations in ovarian cancer patients from the Volga-Ural region. . 2012;(1):100-101. DOI: https://doi.org/10.1111/j.1399-0004.2011.01824.xKluska A, Balabas A, Piatkowska M, et al. PALB2 mutations in BRCA1/2-mutation negative breast and ovarian cancer patients from Poland. . 2017;(1):1-6. DOI: https://doi.org/10.1186/s12920-017-0251-8Rein HL, Bernstein KA, Baldock RA. RAD51 paralog function in replicative DNA damage and tolerance. . 2021;:86-91. DOI: https://doi.org/10.1016/j.gde.2021.06.010Meindl A, Hellebrand H, Wiek C, et al. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. . 2010;(5):410-414. DOI: https://doi.org/10.1038/ng.569Loveday C, Turnbull C, Ramsay E, et al. Germline mutations in RAD51D confer susceptibility to ovarian cancer. 2011;(9):879-882. DOI: https://doi.org/10.1038/ng.893Thompson ER, Rowley SM, Sawyer S, et al. Analysis of RAD51D in ovarian cancer patients and families with a history of ovarian or breast cancer. . 2013;(1):e54772. DOI: https://doi.org/10.1371/journal.pone.0054772Coulet F, Fajac A, Colas C, et al. Germline RAD51C mutations in ovarian cancer susceptibility. 2013;(4):332-336. DOI: &nbsp;https://doi.org/10.1111/j.1399-0004.2012.01917.xPelttari LM, Kiiski J, Nurminen R, et al. A Finnish founder mutation in RAD51D: analysis in breast, ovarian, prostate, and colorectal cancer. . 2012;(7):429-432. DOI: http://dx.doi.org/10.1136/jmedgenet-2012-100852Yang X, Song H, Leslie G, et al. Ovarian and breast cancer risks associated with pathogenic variants in RAD51C and RAD51D. . 2020;(12):1242-1250. DOI: https://doi.org/10.1093/jnci/djaa030Suszynska M, Ratajska M, Kozlowski P. BRIP1, RAD51C, and RAD51D mutations are associated with high susceptibility to ovarian cancer: mutation prevalence and precise risk estimates based on a pooled analysis of~ 30,000 cases. . 2020;(1):1-11. DOI: https://doi.org/10.1186/s13048-020-00654-3Dawson LM, Smith KN, Werdyani S, et al. A dominant RAD51C pathogenic splicing variant predisposes to breast and ovarian cancer in the Newfoundland population due to founder effect. . 2020;(2):e1070. DOI: &nbsp;https://doi.org/10.1002/mgg3.1070Vuorela M, Pylk&auml;s K, Hartikainen JM, et al. Further evidence for the contribution of the RAD51C gene in hereditary breast and ovarian cancer susceptibility. . 2011;(3):1003-1010. DOI: https://doi.org/10.1007/s10549-011-1677-xMin A, Im SA, Yoon YK, et al. RAD51C-deficient cancer cells are highly sensitive to the PARP inhibitor olaparib. . 2013;(6):865-877.&nbsp;https://doi.org/10.1158/1535-7163.MCT-12-0950Jiang X, Li X, Li W, et al. PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms. . 2019;(4):2303-2313. DOI: https://doi.org/10.1111/jcmm.14133Rutter JL, Smith AM, D&aacute;vila MR, et al. Mutational analysis of the BRCA1‐interacting genes ZNF350/ZBRK1 and BRIP1/BACH1 among BRCA1 and BRCA2‐negative probands from breast‐ovarian cancer families and among early‐onset breast cancer cases and reference individuals. . 2003;(2):121-128. DOI: https://doi.org/10.1002/humu.10238Cantor SB, Guillemette S. Hereditary breast cancer and the BRCA1-associated FANCJ/BACH1/BRIP1. . 2011;(2):253-261. DOI: https://doi.org/10.2217/fon.10.191London TB, Barber LJ, Mosedale G, et al. FANCJ is a structure-specific DNA helicase associated with the maintenance of genomic G/C tracts. . 2008;(52):36132-36139. DOI: https://doi.org/10.1074/jbc.M808152200Voutsadakis IA. Landscape of BRIP1 molecular lesions in gastrointestinal cancers from published genomic studies. . 2020;(11):1197. DOI:&nbsp;https://doi.org/10.3748/wjg.v26.i11.1197Weber-Lassalle N, Hauke J, Ramser J, et al. BRIP1 loss-of-function mutations confer high risk for familial ovarian cancer, but not familial breast cancer. . 2018;(1):1-6. DOI: https://doi.org/10.1186/s13058-018-0935-9Bridge WL, Vandenberg CJ, Franklin RJ, et al. The BRIP1 helicase functions independently of BRCA1 in the Fanconi anemia pathway for DNA crosslink repair.&nbsp;. 2005;(9):953-957. DOI: https://doi.org/10.1038/ng1627Castaneda A, Moyer C, Gillespie JL, et al. BRIP1 mutation does not confer sensitivity to PARP inhibition. . 2019;:87. DOI: https://doi.org/10.1016/j.ygyno.2019.04.205del Valle J, Rofes P, Moreno-Cabrera JM, et al. Exploring the role of mutations in Fanconi anemia genes in hereditary cancer patients. . 2020;(4):829. DOI: https://doi.org/10.3390/cancers12040829Dicks E, Song H, Ramus SJ, et al. Germline whole exome sequencing and large-scale replication identifies FANCM as a likely high grade serous ovarian cancer susceptibility gene. . 2017;(31):50930. DOI:&nbsp;https://doi.org/10.18632/oncotarget.15871Song H, Dicks EM, Tyrer J, et al. Population-based targeted sequencing of 54 candidate genes identifies PALB2 as a susceptibility gene for high-grade serous ovarian cancer. . 2021;(5):305-313. DOI: http://dx.doi.org/10.1136/jmedgenet-2019-106739